Evaxion Biotech (EVAX) Tops Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Evaxion Biotech Announces First Quarter 2022 Financial Results and Provides Business Update
May 11, 2022 7:30 AM EDTReceived regulatory clearance in Australia to initiate phase 2b trial of lead cancer therapy EVX-01 targeting melanomaCompleted recruitment for Phase 1/2a clinical trial for EVX-02 with all patients receiving first doseAnnounced publication on personalized therapy with EVX-01 in patients with metastatic melanoma in the open-access, peer-reviewed medical science journal OncoImmunologyHosted Key Opinion Leader (KOL) webinar with acclaimed experts on metastatic melanoma and personalized cancer immunotherapiesEnded first quarter with cash and cash equivalents of $31.4 millionEvaxion will host webcast and conference call today, May 11, at 8:30 am EDT
COPENHAGEN, Denmark, May... More
